Senators are raising alarms about how drug companies are using telehealth platforms. A recent Senate investigation has revealed that direct-to-consumer telehealth platforms operated by pharmaceutical companies appear to steer patients toward their own medications.
Pharma Telehealth Payments Under Scrutiny
Drug companies’ telehealth dealings face Senate investigation for potential kickbacks.
Did you know? Senators are scrutinizing payments made by major drug manufacturers to telehealth companies. This scrutiny stems from concerns that these arrangements might influence prescribing patterns, potentially leading to kickbacks.
The investigation specifically highlights how companies like Lilly and Pfizer are channeling payments. The findings suggest a direct link between these payments and the steering of patients toward the drugs these companies manufacture. This practice raises significant ethical and regulatory questions within the healthcare industry.
Healthcare Operations and Technology Advancements
In other news, Ensemble Health Partners has announced a strategic partnership. They will now manage the revenue cycle operations for Methodist Le Bonheur Healthcare. This collaboration will span across all six of Methodist Le Bonheur Healthcare’s hospitals located in Tennessee.
Meanwhile, healthcare technology is seeing innovation. CareCloud has launched a new electronic health record (EHR) system specifically designed for dermatology practices. This system is AI-driven and fully integrated, aiming to streamline workflows and improve patient care within the specialty.
